Experience with the use of yttrium-90 ibritumomab tiuxetan (Zevalin) in relapsed follicular lymphoma

被引：0
|
作者：
Demeter, J.
Balassa, K.
Domotor, M.
Egyed, M.
Gasztonyi, Z.
Aryab, H.
Gurzo, M.
Ivayi, J.
Klucsik, Zs.
Sreter, L.
Nagy, Zs.
机构：
[1] Semmelweis Univ, Sopron Hosp, Dept Med, Kaposvar, Hungary
[2] Kaposi Mor Teaching Hosp, Dept Internal Med, Kaposvar, Hungary
[3] Petz Aladar Hosp Gyor, Kecskemet, Hungary
[4] Dept Med 2, Kecskemet, Hungary
[5] Markusovsky Hosp, Dept Internal Med, Szombathely, Hungary
来源：
BLOOD REVIEWS | 2007年 / 21卷
关键词：
D O I：
10.1016/S0268-960X(07)70245-X
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S138 / S139
页数：2
相关论文
共 50 条
  • [31] Extravazation of therapeutic yttrium-90-ibritumomab tiuxetan (Zevalin®):: A case report
    Williams, Gethin
    Palmer, Matthew R.
    Parker, J. Anthony
    Joyce, Robin
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2006, 21 (02) : 101 - 105
  • [32] Radioimmunotherapy with 90Y-ibritumomab tiuxetan for a hemodialysis patient with relapsed follicular lymphoma
    Fukuno, Kenji
    Tsurumi, Hisashi
    Yamada, Toshiki
    Iida, Takayoshi
    Takahashi, Takeshi
    Moriwaki, Hisataka
    LEUKEMIA & LYMPHOMA, 2013, 54 (12) : 2731 - 2733
  • [33] Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): The role of the nuclear medicine physician
    Conti, PS
    SEMINARS IN NUCLEAR MEDICINE, 2004, 34 (01) : 2 - 3
  • [34] A phase ii study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL)
    Younes, A
    Rodriguez, M
    Pro, B
    McLaughlin, P
    Romaguera, J
    Hagemeister, F
    Wang, M
    ANNALS OF ONCOLOGY, 2005, 16 : 96 - 96
  • [35] A phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL).
    Oki, Y
    Pro, B
    Delpassand, E
    Ballaster, V
    McLaughlin, P
    Romaguera, J
    Wang, M
    Hagemeister, FB
    Younes, A
    BLOOD, 2004, 104 (11) : 720A - 720A
  • [36] Yttrium-90 ibritumomab tiuxetan with high-dose carmustine, cytarabine, etoposide, and melphalan (Zevalin-BEAM) conditioning regimen in relapsed aggressive non-Hodgkin lymphoma
    Tan, S. M.
    Lau, N. S.
    Lim, S. M.
    Zanapiah, M.
    Chang, K. M.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S440 - S441
  • [37] Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)
    Gordon, LI
    SEMINARS IN ONCOLOGY, 2003, 30 (06) : 23 - 28
  • [38] Experience with 90Y-ibritumomab tiuxetan for relapsed classical Hodgkin lymphoma
    Younes, A.
    Wong, F.
    ANNALS OF ONCOLOGY, 2009, 20 (06) : 1147 - 1148
  • [39] Response evaluation of yttrium-90 ibritumomab-tiuxetan (Zevalin®) with fluor-18 FluoroDeoxyGlucose (FDG-PET)
    Huglo, D.
    Morschhauser, F.
    Prangere, T.
    Raynaud, F.
    Steinling, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S188 - S188
  • [40] Yttrium-90 ibritumomab tiuxetan (zevalin) induces high response rates in previously treated patients with diffuse large B cell lymphoma (DLBCL)
    Morschhauser, F
    Huglo, D
    Martinelli, G
    Paganelli, G
    Zinzani, P
    Hadjiyiannakis, D
    Liberati, A
    Illidge, T
    Milpied, N
    Kalmus, J
    Morel, P
    Reimann, U
    Marcus, R
    ANNALS OF ONCOLOGY, 2005, 16 : 54 - 54
12345